Jeremy Bender Sells 12,500 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Stock

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWNGet Rating) CEO Jeremy Bender sold 12,500 shares of the company’s stock in a transaction dated Monday, November 21st. The shares were sold at an average price of $20.76, for a total transaction of $259,500.00. Following the transaction, the chief executive officer now directly owns 1,204,924 shares of the company’s stock, valued at approximately $25,014,222.24. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Jeremy Bender also recently made the following trade(s):

  • On Wednesday, November 16th, Jeremy Bender sold 1,513 shares of Day One Biopharmaceuticals stock. The shares were sold at an average price of $21.46, for a total transaction of $32,468.98.
  • On Tuesday, November 1st, Jeremy Bender sold 12,500 shares of Day One Biopharmaceuticals stock. The shares were sold at an average price of $20.03, for a total transaction of $250,375.00.
  • On Monday, October 3rd, Jeremy Bender sold 12,500 shares of Day One Biopharmaceuticals stock. The shares were sold at an average price of $20.05, for a total transaction of $250,625.00.

Day One Biopharmaceuticals Stock Down 2.5 %

NASDAQ DAWN opened at $21.14 on Friday. Day One Biopharmaceuticals, Inc. has a 12 month low of $5.44 and a 12 month high of $28.35. The company has a 50-day moving average of $20.12 and a 200-day moving average of $18.07.

Institutional Trading of Day One Biopharmaceuticals

Institutional investors have recently modified their holdings of the company. TCI Wealth Advisors Inc. purchased a new stake in shares of Day One Biopharmaceuticals during the 2nd quarter worth about $35,000. Silverarc Capital Management LLC purchased a new stake in shares of Day One Biopharmaceuticals during the 2nd quarter worth about $1,888,000. ACG Wealth purchased a new stake in shares of Day One Biopharmaceuticals during the 2nd quarter worth about $32,000. State Board of Administration of Florida Retirement System purchased a new stake in shares of Day One Biopharmaceuticals during the 2nd quarter worth about $246,000. Finally, Deerfield Management Company L.P. Series C grew its holdings in shares of Day One Biopharmaceuticals by 68.3% during the 2nd quarter. Deerfield Management Company L.P. Series C now owns 3,512,123 shares of the company’s stock worth $62,867,000 after purchasing an additional 1,425,674 shares during the period. Hedge funds and other institutional investors own 95.40% of the company’s stock.

About Day One Biopharmaceuticals

(Get Rating)

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma.

Further Reading

Insider Buying and Selling by Quarter for Day One Biopharmaceuticals (NASDAQ:DAWN)

Receive News & Ratings for Day One Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Day One Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.